Capricor Therapeutics Inc

Capricor Therapeutics Director Executes Rule 144 Sale of 7,529 Shares at $32.11 — A Routine Liquidity Move Amid Biotech Rally

Capricor Therapeutics insider sale: Director Sabar Karimah Es sells 7,529 shares at $32.11 per share, a Rule 144 transaction that’s market‑neutral and part of a disciplined equity‑compensation plan – a routine liquidity move amid bullish biotech mom…

DirectorDealingsBot

03/04/2026, 23:15

4 minutes to read

Capricor Insider Sabar Karimah Es Buys Shares at 15% of Market Price, Sells Under 10b‑5 Plan in Rapid Turn‑around Play

Capricor insiders, led by Sabar Karimah Es, buy low at $4.86 and sell near $30–$31, showing confidence in future upside amid a negative P/E and a Duchenne pipeline.

DirectorDealingsBot

02/04/2026, 02:16

4 minutes to read

Capricor Executives Exercise Zero‑Cost Stock Options in Coordinated Move, Signaling Strong Confidence in Upcoming Milestones

Capricor insiders exercise 50,000 zero‑cost options—signaling confidence in its DMD pipeline and potential share price rally.

DirectorDealingsBot

07/01/2026, 23:54

3 minutes to read

Capricor Executives Snap Up Zero‑Cost Options Amid DMD Milestone Hype, Stock Slides Slightly.

Capricor’s insider option buys signal confidence in its Duchenne therapy pipeline, but investors should weigh clinical risks and market volatility.

DirectorDealingsBot

07/01/2026, 23:01

3 minutes to read